These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18094111)

  • 1. Immunity to a self-derived, channel-forming peptide in the respiratory tract.
    van Ginkel FW; Iwamoto T; Schultz BD; Tomich JM
    Clin Vaccine Immunol; 2008 Feb; 15(2):260-6. PubMed ID: 18094111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice.
    Shekar A; Ramlal S; Jeyabalaji JK; Sripathy MH
    Med Microbiol Immunol; 2019 Feb; 208(1):89-100. PubMed ID: 30209565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice.
    Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ
    Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus.
    Liang XP; Lamm ME; Nedrud JG
    J Immunol; 1988 Sep; 141(5):1495-501. PubMed ID: 2842395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses.
    Okahashi N; Yamamoto M; Vancott JL; Chatfield SN; Roberts M; Bluethmann H; Hiroi T; Kiyono H; McGhee JR
    Infect Immun; 1996 May; 64(5):1516-25. PubMed ID: 8613355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization.
    Rodríguez A; Troye-Blomberg M; Lindroth K; Ivanyi J; Singh M; Fernández C
    Vaccine; 2003 Jan; 21(5-6):458-67. PubMed ID: 12531644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal immunization with the 40-kDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice.
    Cai Y; Kurita-Ochiai T; Kobayashi R; Hashizume T; Yamamoto M
    J Oral Sci; 2013; 55(2):107-14. PubMed ID: 23748449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for early aging in the mucosal immune system.
    Koga T; McGhee JR; Kato H; Kato R; Kiyono H; Fujihashi K
    J Immunol; 2000 Nov; 165(9):5352-9. PubMed ID: 11046071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
    Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
    Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
    Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
    Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.
    Jackson RJ; Fujihashi K; Xu-Amano J; Kiyono H; Elson CO; McGhee JR
    Infect Immun; 1993 Oct; 61(10):4272-9. PubMed ID: 8406816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.
    Ohmura M; Yamamoto M; Kiyono H; Fujihashi K; Takeda Y; McGhee JR
    Vaccine; 2001 Dec; 20(5-6):756-62. PubMed ID: 11738739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal vaccination with peptides and cholera toxin subunit B as adjuvant to enhance mucosal and systemic immunity to respiratory syncytial virus.
    Kim HJ; Kim JK; Seo SB; Lee HJ; Kim HJ
    Arch Pharm Res; 2007 Mar; 30(3):366-71. PubMed ID: 17424945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.
    Wu HY; Russell MW
    Vaccine; 1998; 16(2-3):286-92. PubMed ID: 9607044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal and systemic adjuvant effects of cholera toxin and Cry1Ac protoxin on the specific antibody response to HIV-1 C4/V3 peptides are different and depend on the antigen co-administered.
    Esquivel-Pérez R; Moreno-Fierros L
    Viral Immunol; 2005; 18(4):695-708. PubMed ID: 16359236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization of cocktail/fusion protein containing Tir along with ΔG active fragment of Zot as mucosal adjuvant confers enhanced immunogenicity and reduces E. coli O157:H7 shedding in mice.
    Shekar A; Ramlal S; Jeyabalaji JK; Sripathy MH
    Int Immunopharmacol; 2018 Oct; 63():211-219. PubMed ID: 30103196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunological consequences of feeding cholera toxin. I. Feeding cholera toxin suppresses the induction of systemic delayed-type hypersensitivity but not humoral immunity.
    Kay RA; Ferguson A
    Immunology; 1989 Mar; 66(3):410-5. PubMed ID: 2703255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.